Join the tidal wave of support for personalized and regenerative medicine
All across the globe, government and industry support is gaining incredible momentum for the science and technologies of precision/personalized medicine, stem cell research, and regenerative medicine. And for many excellent reasons.
Advances in these areas in the United States, Canada, and beyond are changing and saving lives every day.
We are so pleased to share some of the recent good news surrounding these efforts with you.
Read on and be sure to share your news and stories with us, too!
Lattice Biologics, Inc.
Big Support for Precision Medicine: The White House's $215 Million Initiative
During his State of the Union Address, President Obama announced the launch of his new Precision Medicine Initiative in the form of a $215 million investment) for the 2016 Budget. The goal of the "personalized medicine" effort is to help deliver the right treatment for each patient when they need it - instead of a one-size-fits-all approach. The initiative includes:
$130 million to the National Institutes of Health (NIH)
$70 million to the National Cancer Institute (NCI)
$10 million to the Food and Drug Administration (FDA)
$5 million to the Office of the National Coordinator for Health Information Technology (ONC)
Key Points from the New York Times:
White House officials said the "precision medicine initiative" would begin with a down payment of $215 million in the president's budget request for the fiscal year that starts Oct. 1.
Precision medicine, also known as personalized or individualized medicine, "gives us one of the greatest opportunities for new medical breakthroughs that we have ever seen," Mr. Obama said at a White House event attended by patients' advocates, researchers, and drug and biotechnology company executives.
"We have been waiting for this for many, many years," Dr. José Baselga, the chief medical officer at Memorial Sloan Kettering Cancer Center in New York, said of the project. "We dreamed of this. We can mine the genome of tumors from our patients, identify mutations responsible for the tumors and accelerate improvements in patient care."
(Excerpts from "U.S. to Collect Genetic Data to Hone Care" By Robert Pear, The New York Times, Jan. 30, 2015)
Read the whole article here:
"U.S. to Collect Genetic Data to Hone Care" - NY Times
Get the Facts! Check out the White House's
"FACT SHEET: President Obama's Precision Medicine Initiative"
| Support for Regenerative Medicine continues in Canada: the Ontario Institute for Regenerative Medicine (OIRM)
"Ontario invests in better health and economic opportunity through support for Ontario Institute for Regenerative Medicine"
June 19, 2015 Toronto, ON - A new $25 million commitment positions Ontario to be an early adopter of new treatments and technologies emerging from research and commercial developments in regenerative medicine.
The Honourable Reza Moridi, Minister of Research and Innovation, announced today renewed support for the Ontario Institute for Regenerative Medicine (OIRM), a network of Ontario-based stem cell and regenerative medicine programs operating in partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) along with Ontario's leading health and research institutions. OIRM will invest in translational research for degenerative diseases such as heart disease, autoimmune disorders, diabetes and vision loss, and seeks to revolutionize the treatment of these and other diseases through the development and commercialization of stem cell-based products and therapies.
Read the whole article here:
| Lattice Biologics, Inc. teams with Sunnybrook Research Institute to submit a grant proposal to the OIRM
Lattice is thrilled to be partnering with Sunnybrook Research Institute (SRI) to apply for The Disease Challenge Team Grant from OIRM. SRI is a fully affiliated research and teaching hospital with the University of Toronto.
The Ontario Institute for Regenerative Medicine recently announced a call for grant proposals related to the application of stem cell research to regenerative medicine and improved health outcomes. "The Disease Challenge Team Grant will support projects that are developing novel cellular or stem cell-related therapeutic approaches to tissue repair and regeneration for specific diseases. Proposals must clearly identify the translational bench to bedside path of the research and where the proposed research stands along the path. Partnerships with foundations, institutions, health charities or industry are an important and mandatory component of the project. Projects that principally involve basic research for enabling/problem solving technologies are encouraged to apply to the New Ideas Grant program."
Commercialization and translation are an important program components of this program, which requires that investigators demonstrate that the following areas:
Patent and intellectual property progress
Technology and manufacturing scale-up
Regulatory and clinical trials expertise
Industry receptors and/or out-licensing or company creation
Learn more about OIRM funding opportunities here:
Learn more about Sunnybrook Research Institute here:
Lattice Approved by AZ Commerce Authority for Angel Investor Tax Credit
In what is a significant achievement along Lattice Biologics' funding journey, we have been approved for the Angel Investor Tax Credit.
"The main objective of the Angel Investment tax credit is to expand early stage investments in targeted Arizona small businesses. The tax credit accomplishes this goal by providing tax credits to investors who make capital investment in small businesses certified by the Arizona Commerce Authority (ACA)."
The Angel Investment tax credit is established under A.R.S. §41-1518. In early 2011, Governor Jan Brewer signed into law HB2001 - Arizona's Competitiveness Package. This legislation marked a new level of Arizona commitment, making it easier for existing Arizona companies to be more prosperous. It also established Arizona as one of the most desirable places for expanding companies to do business. New benefits for 2014 include the elimination of capital gains tax on income derived from investments in companies certified by ACA. (A.R.S. §43-1022(27)).
View the businesses certified under this program here:
Angel Investor List
Lattice Accepted into the Centre for Commercialization of Regenerative Medicine (CCRM)
The Centre for Commercialization of Regenerative Medicine (CCRM) has selected Lattice Biologics as a new Member of its Industry Consortium.
"CCRM's founding industry consortium represents key sectors of the Regenerative Medicine (RM) industry - pharmaceutical, devices, reagents, tools, biomaterials and cell therapies. They all have the same objective: to utilize the translational platforms developed by CCRM to enable new opportunities and to address real-life bottlenecks in their RM businesses. The industry consortium consists of large multinationals, small-medium enterprises (SME) and emerging biotechnology companies. The industry consortium provides market knowledge and a ready supply of global receptors for technologies and products generated by CCRM and its partners."
"CCRM is a Canadian not-for-profit, public-private consortium funded by the Government of Canada's Networks of Centres of Excellence program, six Ontario-based institutional partners, and more than 40 companies representing the key sectors of the regenerative medicine industry. CCRM supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies."
CCRM was the Silver Sponsor of the 10th Annual World Stem Cells & Regenerative Medicine Congress in London this May.
Learn more about the Industry Consortium here: CCRM
| SHARE THE WORD
Know someone who might be interested in our regenerative and personalized medicine updates?
Click to share this newsletter with your team, colleagues, and contacts.
If you have received this newsletter from a friend, click the box above to sign-up and receive your own updates.
| SEVEN PEOPLE WHOSE LIVES WERE CHANGED BY PRECISION MEDICINE
William Elder, Jr. was diagnosed with cystic fibrosis (CF) at the age of eight, but is alive today at age 27 thanks to Kalydeco, a treatment of a particular form for his cystic fibrosis and a remarkable drug that treats the underlying cause of his CF, rather than the symptoms.
At the age of six, Emily Whitehead was the first pediatric patient to be treated with a new kind of cancer immunotherapy. She was cancer free only 28 days later. "If you didn't know what happened to her, and you saw her now, you would have no idea what she has been through," says Emily's Mom. The pioneering cancer immunotherapy trial at the Children's Hospital of Philadelphia that saved Emily's life was named a "2013 Breakthrough of the Year" by Science Magazine.
Melanie Nix tested positive for the BRCA gene mutations linked to breast cancer in 2008. After 16 rounds of chemotherapy and breast reconstruction surgery, she had to have both ovaries removed to further reduce risks of cancer in the future. But Melanie is now cancer free thanks to precision medicine. Melanie says that this type of tailored treatment gave her hope. "Precision medicine offers the hope that by the time my daughter is at an age when she considers genetic testing, new, targeted treatments will be available to give her additional choices for preserving her health," she said.
Beatrice Rienhoff's eyes were spaced wider than usual, her leg muscles were weak, and she couldn't gain weight. Her father, Hugh Rienhoff, a trained clinical geneticist, took notice and wanted to help. After six years, he and his team of scientific volunteers identified the cause of her condition. Hugh lead his team to identify a variant responsible for his daughter's condition and this research gave rise to the description of a whole new syndrome. The team continues to use precision medicine to learn more about the new syndrome and further study genetic variation to help those like his daughter. Today, Beatrice is living a full life.
(Excerpts from "Precision Medicine Is Already Working to Cure Americans: These Are Their Stories" By Chris Evans, www.Whitehouse.gov)
Read on for their full stories as well as those of Kareem Abdul-Jabbar and Keith Yamamoto here "Survivor Stories"
|GET TO KNOW LATTICE
Lattice Biologics Inc. is an emerging leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration.
We develop, manufacture, and market biologic products to domestic and international markets.
Our products are used in a variety of applications, including:
Enhancing fusion in spine surgery
Enhancing breast reconstruction post mastectomy for breast cancer patients
Sports medicine indications, including ACL repair
Promotion of bone regeneration in foot and ankle surgery
Enhancing wound repair in burn victims
Subchondral bone defect repair in knee and other joint surgeries
Contact us today to learn more about our products and technologies.
Click here to download our Executive Summary.